Monday, November 30, 2020

Market Analysts see Sarepta Therapeutics Inc. [SRPT] gaining to $183. Time to buy?

Must read

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

Sarepta Therapeutics Inc. [NASDAQ: SRPT] slipped around -6.23 points on Thursday, while shares priced at $153.60 at the close of the session, down -3.90%. Sarepta Therapeutics Inc. stock is now 19.03% up from its year-to-date (YTD) trading value. SRPT Stock saw the intraday high of $162.4776 and lowest of $152.72 per share. The company’s 52-week high price is 161.43, which means current price is +96.77% above from all time high which was touched on 06/11/20.

Compared to the average trading volume of 973.34K shares, SRPT reached a trading volume of 1051885 in the most recent trading day, which is why market watchdogs consider the stock to be active.


My #1 Stock Trade This Year (HINT: It's a COVID-19 Play)

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<

Sponsored


What do top market gurus say about Sarepta Therapeutics Inc. [SRPT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRPT shares is $192.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRPT stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Mizuho have made an estimate for Sarepta Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2020. While these analysts kept the previous recommendation, Guggenheim raised their target price to Buy. The new note on the price target was released on November 01, 2019, representing the official price target for Sarepta Therapeutics Inc. stock. Previously, the target price had yet another drop from $196 to $170, while Needham kept a Buy rating on SRPT stock. On July 09, 2019, analysts increased their price target for SRPT shares from 165 to 220.

The Average True Range (ATR) for Sarepta Therapeutics Inc. is set at 7.16, with the Price to Sales ratio for SRPT stock in the period of the last 12 months amounting to 28.81. The Price to Book ratio for the last quarter was 10.25, with the Price to Cash per share for the same quarter was set at 28.41. Price to Free Cash Flow for SRPT in the course of the last twelve months was 44.28 with Quick ratio for the last quarter at 7.70.

How has SRPT stock performed recently?

Sarepta Therapeutics Inc. [SRPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.92. With this latest performance, SRPT shares gained by 15.58% in over the last four-week period, additionally plugging by 44.67% over the last 6 months – not to mention a rise of 28.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRPT stock in for the last two-week period is set at 58.88, with the RSI for the last a single of trading hit 55.91, and the three-weeks RSI is set at 60.05 for Sarepta Therapeutics Inc. [SRPT]. The present Moving Average for the last 50 days of trading for this stock 128.83, while it was recorded at 155.35 for the last single week of trading, and 110.11 for the last 200 days.

Sarepta Therapeutics Inc. [SRPT]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sarepta Therapeutics Inc. [SRPT] shares currently have an operating margin of -137.10 and a Gross Margin at +84.92. Sarepta Therapeutics Inc.’s Net Margin is presently recorded at -187.77.

Return on Total Capital for SRPT is now -34.71, given the latest momentum, and Return on Invested Capital for the company is -47.66. Return on Equity for this stock declined to -77.29, with Return on Assets sitting at -41.28. When it comes to the capital structure of this company, Sarepta Therapeutics Inc. [SRPT] has a Total Debt to Total Equity ratio set at 90.13. Additionally, SRPT Total Debt to Total Capital is recorded at 47.41, with Total Debt to Total Assets ending up at 40.46. Long-Term Debt to Equity for the company is recorded at 89.18, with the Long-Term Debt to Total Capital now at 46.90.

Reflecting on the efficiency of the workforce at the company, Sarepta Therapeutics Inc. [SRPT] managed to generate an average of -$962,416 per employee. Receivables Turnover for the company is 4.81 with a Total Asset Turnover recorded at a value of 0.22.Sarepta Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 8.30.

Earnings analysis for Sarepta Therapeutics Inc. [SRPT]

With the latest financial reports released by the company, Sarepta Therapeutics Inc. posted -3.74/share EPS, while the average EPS was predicted by analysts to be reported at -1.37/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -173.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sarepta Therapeutics Inc. go to -0.20%.

Insider trade positions for Sarepta Therapeutics Inc. [SRPT]

There are presently around $11,837 million, or 95.10% of SRPT stock, in the hands of institutional investors. The top three institutional holders of SRPT stocks are: FMR LLC with ownership of 7,414,794, which is approximately -9.324% of the company’s market cap and around 4.90% of the total institutional ownership; VANGUARD GROUP INC, holding 6,544,789 shares of the stock with an approximate value of $1.05 billion in SRPT stocks shares; and BLACKROCK INC., currently with $781.16 million in SRPT stock with ownership of nearly 5.326% of the company’s market capitalization.

Positions in Sarepta Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 189 institutional holders increased their position in Sarepta Therapeutics Inc. [NASDAQ:SRPT] by around 7,952,837 shares. Additionally, 198 investors decreased positions by around 6,932,545 shares, while 57 investors held positions by with 59,171,461 shares. The mentioned changes placed institutional holdings at 74,056,843 shares, according to the latest SEC report filing. SRPT stock had 52 new institutional investments in for a total of 1,406,926 shares, while 72 institutional investors sold positions of 2,093,806 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.